OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drugProactive Investors • 10/06/26
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainGlobeNewsWire • 10/06/26
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific ConferencesGlobeNewsWire • 09/29/26
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026GlobeNewsWire • 09/09/26
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare ConferenceGlobeNewsWire • 09/08/26
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and DirectorGlobeNewsWire • 07/22/26
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 07/21/26
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plansProactive Investors • 07/20/26
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 PlansGlobeNewsWire • 07/20/26
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal painProactive Investors • 07/08/26
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal PainGlobeNewsWire • 07/08/26
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology SymposiumGlobeNewsWire • 07/07/26
OKYO Pharma expands scientific advisory board with cornea expert - ICYMIProactive Investors • 05/23/26
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory BoardProactive Investors • 05/19/26
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhDGlobeNewsWire • 05/19/26
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayGlobeNewsWire • 04/29/26